In February, Democratic Socialists of America (DSA) reached the milestone of 100,000 members, with nearly 14,000 of them in New York City alone. The election of Zohran Mamdani, a longtime DSA activist ...

The race for LA mayor has two candidates from the Democratic Socialists of America (DSA), including City Council member Nithya Raman. It is worth a look at the DSA’s political platform. The first item ...

The New York City chapter of the Democratic Socialists of America often defines itself by running against the machine. That was the primary way then-Assembly candidate Zohran Mamdani differentiated ...

A specter is haunting New York politics – the specter of the Democratic Socialists of America. Over the past 10 years, the socialist organization has had its ups and downs, but recently it has been on ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

Ricursive Intelligence, a startup building an AI system to design and automatically improve AI chips, has raised $300 million at a $4 billion valuation. The company said Monday the round was led by ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...

New York City’s chapter of the Democratic Socialists of America (DSA) is organizing a large-scale effort to mobilize thousands of activists to respond to anticipated federal immigration enforcement ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...